FemSelect
FemSelect is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at FemSelect.
FemSelect is a company.
Key people at FemSelect.
Key people at FemSelect.
FemSelect is a women-led medical technology company specializing in innovative solutions for pelvic organ prolapse (POP), a condition affecting one in four adult women. Its flagship product, the EnPlace® system, is a minimally invasive, mesh-free, and dissection-free technology designed to treat POP with fewer complications, reduced pain, minimal scarring, and quicker recovery compared to traditional surgical methods. FemSelect serves women suffering from pelvic floor disorders, offering them safer and more accessible treatment options that preserve uterine conservation and improve quality of life. The company is expanding globally and has recently broadened its portfolio to include treatments for urinary incontinence through a partnership with Elidah, reflecting strong growth momentum fueled by successful funding rounds and strategic partnerships[1][2][3].
Founded originally in Israel, FemSelect emerged from the need to address the significant unmet medical needs in women’s pelvic health with less invasive and more patient-friendly technologies. The company was co-led by Renee Selman (Executive Chairwoman) and later appointed Sasha Schrode as CEO, who brought extensive healthcare innovation and commercial expertise from her previous leadership at Serpex Medical. The idea for EnPlace grew from clinical experience and the desire to offer a safer alternative to mesh-based surgeries, which have been associated with complications. Early traction included FDA clearance, CE marking, and strategic partnerships such as the sales agreement with LiNA Medical USA to accelerate U.S. market penetration. The company’s relocation of its headquarters to the U.S. aligns with its largest market focus and growth ambitions[2][4][5].
FemSelect rides the growing trend of personalized, minimally invasive medical technologies that prioritize patient safety and quality of life, especially in women’s health—a historically underserved area. The timing is critical as awareness of pelvic organ prolapse and urinary incontinence rises, alongside increasing demand for alternatives to traditional mesh surgeries. Market forces such as regulatory scrutiny on mesh products and a global push for women-centric healthcare innovations favor FemSelect’s approach. By expanding its product portfolio and geographic footprint, FemSelect influences the broader ecosystem by setting new standards for pelvic health treatment and empowering healthcare providers with advanced, patient-friendly tools[1][3][5].
FemSelect is poised for significant growth as it leverages recent funding, leadership enhancements, and strategic U.S. market positioning. Future trends shaping its journey include increasing awareness of pelvic health issues, technological advances in minimally invasive procedures, and expanding digital health integration for patient monitoring and education. The company’s influence is likely to evolve from a niche innovator to a global leader in women’s pelvic health solutions, potentially expanding into adjacent markets and continuing to build a comprehensive platform of women’s health technologies. FemSelect’s mission to redefine care for millions of underserved women worldwide remains central as it scales its impact[2][3][5].
